This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| ANSM (France) | |
|---|---|
| Name | ANSM |
| Native name | Agence nationale de sécurité du médicament et des produits de santé |
| Formation | 2012 |
| Type | Regulatory agency |
| Headquarters | Paris |
| Region served | France |
| Leader title | Director General |
ANSM (France) is the French national agency responsible for the regulation of medicinal products and health products. It operates within the framework of French institutions such as the Ministry of Health (France), interfaces with European bodies including the European Medicines Agency, and participates in international forums like the World Health Organization. The agency's remit touches on pharmaceuticals, medical devices, biologics, and blood products and interacts with stakeholders such as Institut Pasteur, INSERM, and major industry actors including Sanofi and Pfizer.
The agency was created in 2012, succeeding predecessors such as the Agence française de sécurité sanitaire des produits de santé and inheriting mandates from bodies linked to the Ministry of Social Affairs and Health (France). Its formation followed high-profile public health episodes involving companies like Servier and events associated with products scrutinized after controversies such as the Mediator (drug) affair. The establishment drew on earlier regulatory frameworks shaped by European instruments like the Directive 2001/83/EC and consequential French legislation including statutes from the French Parliament and rulings influenced by the Council of State (France). Over time, the agency has adjusted procedures in response to crises involving vaccines, medical devices, and clinical investigations tied to institutions such as Assistance Publique–Hôpitaux de Paris and research centres like CNRS.
ANSM is structured with executive leadership reporting to the Ministry of Health (France), overseen by an internal board and advisory committees populated by representatives from entities such as Haute Autorité de santé, Caisse nationale de l'assurance maladie, and professional orders like the Ordre des Médecins. Its governance model includes scientific committees drawing experts from INSERM, Université Paris Cité, and international regulators including European Medicines Agency delegates. Legal oversight involves interaction with judicial bodies such as the Conseil d'État (France) and parliamentary commissions including the Parliament of France health committees. The agency employs inspectors who collaborate with regional health agencies such as Agence Régionale de Santé and specialized units coordinating with manufacturers like Roche and laboratories including Institut Curie.
ANSM authorizes marketing and supervises distribution of products interacting with entities such as Sanofi, Novartis, and Johnson & Johnson. It evaluates clinical trial applications submitted by sponsors including academic centres like Institut Pasteur and pharmaceutical firms seeking approvals under EU frameworks like the European Medicines Agency centralized procedure. The agency issues opinions affecting reimbursement decisions coordinated with bodies such as Haute Autorité de santé and monitors advertising practices alongside enforcement partners such as the Direction générale de la concurrence, de la consommation et de la répression des fraudes. It also regulates blood products in liaison with organizations like Établissement français du sang and coordinates recalls with national law enforcement and customs authorities including the Gendarmerie nationale when safety concerns arise.
ANSM's product assessment process involves dossier review referencing guidance from European Medicines Agency guidelines, clinical trial oversight drawing on Good Clinical Practice as promulgated by International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use, and manufacturing inspections guided by Good Manufacturing Practice standards used by firms like Pfizer and Sanofi. The agency operates authorization pathways for orphan medicines in line with Orphan Drug Act-style EU provisions and fast-track mechanisms that mirror procedures at regulators such as the Food and Drug Administration. It convenes expert panels including members from INSERM and university hospitals to assess benefit–risk, and publishes decisions subject to judicial review by bodies such as the Conseil d'État (France).
Pharmacovigilance systems managed by ANSM collect reports from pharmacovigilance centres in networks associated with university hospitals like Assistance Publique–Hôpitaux de Paris, laboratories such as Institut Pasteur, and industry partners including Roche. The agency analyzes safety signals using databases interoperable with systems at the European Medicines Agency and exchanges information under international arrangements with the World Health Organization pharmacovigilance programme. Safety measures have included market withdrawals and risk-minimization measures implemented after incidents involving products reviewed in collaboration with the Haute Autorité de santé and emergency response coordination with Ministry of Health (France) crisis units.
ANSM engages in regulatory science initiatives and collaborates with research organisations such as INSERM and CNRS to refine evaluation methods for advanced therapies including cell and gene therapies developed at centres like Institut Pasteur and multinational companies like Novartis. It contributes to European projects coordinated by the European Medicines Agency and participates in networks such as the International Coalition of Medicines Regulatory Authorities. Partnership activities extend to academic consortia at universities such as Université de Paris and hospitals including Hôpital Universitaire Pitié-Salpêtrière to pilot adaptive trial designs and real-world evidence generation.
ANSM has faced scrutiny post-implementation over responses to high-profile cases linked to products associated with firms like Servier and debates about transparency raised in parliamentary inquiries by the Parliament of France. Critics, including patient associations and professional bodies such as the Ordre des Pharmaciens, have challenged aspects of post-market surveillance and decision-making timeliness, prompting reviews involving the Cour des comptes and legal actions adjudicated by the Conseil d'État (France). Ongoing debates involve balancing expedited access policies resembling those at the Food and Drug Administration with precautionary standards advocated by academic researchers at institutions like Inserm and advocacy groups.
Category:Medical and health organizations based in France